Hospitalization Not Cut by Gilead Sciences, Inc. Heart Drug-Study

April 5, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

NEW ORLEANS, April 4 (Reuters) - Gilead Sciences Inc's (GILD.O) heart drug Ranexa, while found to be effective in reducing chest pain in refractory angina patients, failed to cut hospitalizations in a small 100-patient study.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase II

Gilead Sciences, Inc.